Vaxart, Inc.
Biological Products, (No Diagnostic Substances) · 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
官方登記資料
0位追蹤者
2004成立於
關於 Vaxart, Inc.
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Source: Wikipedia
產業Biological Products, (No Diagnostic Substances)
總部310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
成立時間2004
法律形式C Corporation
狀態營運中
專利58 項專利
ANTIBODIES TARGETING GII GENOTYPES OF HUMAN NOROVIRUSWO2025255258A3 · 2026
ANTIBODIES TARGETING GII GENOTYPES OF HUMAN NOROVIRUSWO2025255258A2 · 2025
關鍵數據
法律資訊
| 法定名稱 | Vaxart, Inc. |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 72444在 SEC EDGAR 上查看 ↗ |
| EIN | 59-1212264 |
| 產業代碼(SIC) | 2836 |
| 登記地址 | 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA |
| 狀態 | 營運中 |
來源: SEC EDGAR · 更新於 2026年10月15日
聯絡方式與連結
地點
310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
這是你的公司嗎?
免費認領此頁面,即可新增標誌、產品、照片與職缺,並回覆評論。
認領此頁面